Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation and Depletion: 2020-2025

Historic Depreciation and Depletion for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to $1.3 million.

  • 4D Molecular Therapeutics' Depreciation and Depletion rose 8.33% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 4.08%. This contributed to the annual value of $4.8 million for FY2024, which is 9.09% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Depreciation and Depletion of $1.3 million as of Q3 2025, which was down 0.00% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Depreciation and Depletion ranged from a high of $1.3 million in Q4 2023 and a low of $400,000 during Q1 2021.
  • Moreover, its 3-year median value for Depreciation and Depletion was $1.2 million (2024), whereas its average is $1.2 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 150.00% in 2022, then dropped by 7.69% in 2024.
  • 4D Molecular Therapeutics' Depreciation and Depletion (Quarterly) stood at $400,000 in 2021, then spiked by 150.00% to $1.0 million in 2022, then surged by 30.00% to $1.3 million in 2023, then fell by 7.69% to $1.2 million in 2024, then climbed by 8.33% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.3 million for Q2 2025, and $1.3 million during Q1 2025.